Table 6.
Month 7 anti-HPV geometric mean titers by day 1 serostatus and PCR status in women, 16–26 years of age who completed the 3-dose 9vHPV vaccine regimena.
|
Females 16–26 years of age (N=7260) |
|||||
|---|---|---|---|---|---|
| HPV type | Day 1 serostatus | Day 1 PCR status | n | GMT (mMU/mL) | (95% CI) |
| HPV 6 | Negative | Negative | 4720 | 901.4 | (881.8, 921.4) |
| Negative | Positive | 113 | 1025.2 | (881.8, 1192.0) | |
| Positive | Negative | 807 | 1876.0 | (1742.2, 2020.1) | |
| Positive | Positive | 109 | 1509.5 | (1287.3, 1770.1) | |
| HPV 11 | Negative | Negative | 4723 | 675.7 | (660.3, 691.4) |
| Negative | Positive | 13 | 618.4 | (331.1, 1155.3) | |
| Positive | Negative | 188 | 1065.9 | (935.0, 1215.0) | |
| Positive | Positive | 14 | 1110.9 | (652.9, 1890.2) | |
| HPV 16 | Negative | Negative | 4799 | 3177.3 | (3109.4, 3246.7) |
| Negative | Positive | 323 | 2941.4 | (2676.1, 3233.1) | |
| Positive | Negative | 492 | 5248.6 | (4848.6, 5681.5) | |
| Positive | Positive | 260 | 4374.0 | (3968.9, 4820.6) | |
| HPV 18 | Negative | Negative | 5334 | 815.9 | (796.0, 836.3) |
| Negative | Positive | 178 | 941.2 | (829.7, 1067.7) | |
| Positive | Negative | 266 | 1917.2 | (1714.3, 2144.0) | |
| Positive | Positive | 86 | 1472.5 | (1236.3, 1753.8) | |
| HPV 31 | Negative | Negative | 5254 | 668.2 | (651.5, 685.3) |
| Negative | Positive | 184 | 625.3 | (553.5, 706.4) | |
| Positive | Negative | 327 | 964.4 | (877.3, 1060.1) | |
| Positive | Positive | 112 | 798.5 | (690.3, 923.7) | |
| HPV 33 | Negative | Negative | 5503 | 424.1 | (414.8, 433.7) |
| Negative | Positive | 101 | 443.3 | (375.7, 523.1) | |
| Positive | Negative | 215 | 665.7 | (582.5, 760.7) | |
| Positive | Positive | 59 | 616.0 | (482.4, 786.7) | |
| HPV 45 | Negative | Negative | 5620 | 255.0 | (248.1, 262.0) |
| Negative | Positive | 130 | 256.9 | (216.8, 304.4) | |
| Positive | Negative | 82 | 354.0 | (279.1, 449.1) | |
| Positive | Positive | 29 | 285.8 | (195.7, 417.4) | |
| HPV 52 | Negative | Negative | 5259 | 385.1 | (376.1, 394.3) |
| Negative | Positive | 275 | 303.5 | (272.8, 337.5) | |
| Positive | Negative | 220 | 547.1 | (488.5, 612.7) | |
| Positive | Positive | 121 | 319.8 | (271.4, 376.7) | |
| HPV 58 | Negative | Negative | 5267 | 493.8 | (482.5, 505.4) |
| Negative | Positive | 158 | 423.3 | (376.1, 476.3) | |
| Positive | Negative | 373 | 618.9 | (559.6, 684.6) | |
| Positive | Positive | 82 | 669.8 | (548.4, 818.0) | |
N=number of subjects who received at least 1 injection of 9vHPV vaccine; n=number of subjects contributing to the analysis.
GMT, geometric mean titer (given in milli-Merck units per milliliter). CI, confidence interval.
a
This analysis population includes subjects who received all 3 doses of correct clinical material, had serology & PCR results at day 1 for the relevant HPV type and had a post-dose 3 or month 7 serology result within acceptable day ranges.